التفاصيل البيبلوغرافية
| العنوان: |
ANTI-NEURODEGENERATIVE DISEASE AGENT |
| Document Number: |
20120035187 |
| تاريخ النشر: |
February 9, 2012 |
| Appl. No: |
13/146840 |
| Application Filed: |
January 25, 2010 |
| مستخلص: |
The present invention has an object to provide a novel agent for anti-neurodegenerative diseases and solves the object by providing an agent for anti-neurodegenerative diseases containing, as an effective ingredient, the compound(s) represented by the following General formula 1: [chemical expression included] wherein in General formula 1, R1 through R3 independently represent a hydrogen atom or an appropriate substituent; Z1 represents a heterocyclic ring and Z2 represents the same or different heterocyclic or aromatic ring as in Z1, wherein the heterocyclic and aromatic rings optionally have a substituent; represents an integer of 0, 1 or 2; p represents an integer of 0 or 1, with the proviso that p is 1 when o is 0 or 2, and p is 0 when o is 1; R1 and R2 do not exist when o is 0, while, when p is 0, R3 does not exist and the binding between the carbon atom to which R2 binds and Z2 is a single bond; X1− represents an appropriate counter anion and q represents an integer of 1 or 2. |
| Inventors: |
Ohta, Hitomi (Okayama, JP); Akita, Kenji (Okayama, JP); Ohta, Tsunetaka (Okayama, JP); Kawata, Toshio (Okayama, JP); Fukuda, Shigeharu (Okayama, JP) |
| Assignees: |
KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (Okayama, JP) |
| Claim: |
1-10. (canceled) |
| Claim: |
11. An anti-neurodegenerative disease agent, which comprises, as an effective ingredient, a compound represented by General formula 1: [chemical expression included] wherein in General formula 1, R1 through R3 independently represent a hydrogen atom or an appropriate substituent; Z1 represents a heterocyclic ring and Z2 represents the same or different heterocyclic or aromatic ring as in Z1, wherein the heterocyclic and aromatic rings optionally have a substituent; o represents an integer of 0, 1 or 2; p represents an integer of 0 or 1, with the proviso that p is 1 when o is 0 or 2, and p is 0 when o is 1; R1 and R2 do not exist when o is 0; R3 does not exist and the binding between the carbon atom to which R2 binds and Z2 is a single bond, when p is 0; X1− represents an appropriate counter anion; and q represents an integer of 1 or 2. |
| Claim: |
12. The anti-neurodegenerative disease agent of claim 11, wherein the compound represented by General formula 1 is any one of the compounds represented by General formula 2 to 5: [chemical expression included] wherein in General formula 2, R4 through R6 each independently represent the same or different aliphatic hydrocarbon group; X2− represents an appropriate counter anion; and m represents an integer of 1 or 2 that forms an electric charge for balancing with the electric charge of a cationic part; [chemical expression included] wherein in General formula 3, R7 through R9 each independently represent the same or different aliphatic hydrocarbon group; X3− represents an appropriate counter anion; and m represents an integer of 1 or 2 that forms an electric charge for balancing with the electric charge of a cationic part; [chemical expression included] wherein in General formula 4, R10 through R12 each independently represent the same or different aliphatic hydrocarbon group; X4− represents an appropriate counter anion; and m represents an integer of 1 or 2 that forms an electric charge for balancing with the electric charge of a cationic part; [chemical expression included] wherein in General formula 5, Z3 represents a heteroaromatic ring which optionally have a substituent; Z4 represents an aromatic or heteroaromatic ring which optionally have a substituent; R13 represents an aliphatic hydrocarbon group which optionally have a substituent; R14 represents a hydrogen atom or an appropriate substituent; and X5− represents an appropriate counter ion. |
| Claim: |
13. The anti-neurodegenerative disease agent of claim 11, wherein the counter anion of the compounds represented by General formula 1 to 5 is iodine ion or a chlorine ion. |
| Claim: |
14. The anti-neurodegenerative disease agent of claim 12, wherein the compound represented by General formula 2 is the compound represented by Chemical formula 2, and wherein the compound represented by General formula 3 is the compound represented by Chemical formula 3: [chemical expression included] |
| Claim: |
15. The anti-neurodegenerative disease agent of claim 11, which further contains one or more pharmaceutically acceptable ingredients. |
| Claim: |
16. The anti-neurodegenerative disease agent of claim 15, wherein said pharmaceutically acceptable ingredients are aqueous media. |
| Claim: |
17. The anti-neurodegenerative disease agent of claim 11, which is a neurocyte degenerative inhibitory agent, a neurocyte protective agent, or an agent for improving motorius degenerative diseases accompanied by neurocyte degeneration. |
| Claim: |
18. The anti-neurodegenerative disease agent of claim 11, wherein said neurocyte is Purkinje's cell of cerebellum. |
| Claim: |
19. The anti-neurodegenerative disease agent of claim 11, wherein said neurodegenerative diseases are Parkinson's disease, dementia, spinocerebellar degeneration, Alzheimer's disease, cerebral infarction, or ataxia. |
| Claim: |
20. The anti-neurodegenerative disease agent of claim 11, which is a brain protective agent, oxidative dysfunction inhibitory agent for brain, inhibitory agent for ischemic brain injury, inhibitory agent for cerebral infarction development, inhibitory agent for cerebral edema, inhibitory agent for delayed neuronal death, agent for normalizing brain failure, oxidative stress inhibitor, antiseptic ulcer agent, hyperglycemia inhibitor, prophylactic and therapeutic agent for eye diseases, organ transplant preservative, necrosis inhibitor for transplanted tissues/organs, prophylactic and therapeutic agent for tissue/organ disorders, prophylactic and therapeutic agent for radiation, antitumor agent, tumor metastasis inhibitory agent, cytotoxic marker inhibitor, prophylactic and therapeutic agent for inflammatory diseases and tissue disorders accompanied thereby, Na—Ca exchange system inhibitor, prophylactic and therapeutic agents for pain and pruritus, protein kinase stimulant, prophylactic and therapeutic agents for mitochondrial encephalomyelopathy, prophylactic and therapeutic agents for arterial occlusion/stenosis, blood-brain-barrier rhexis inhibitor, therapeutic agent for drug dependent diseases, apoptosis inhibitor, formation inhibitor for lipid peroxide, radical scavengers, amyloid 13 peptide aggregation inhibitor, inhibitor for amyloid 13 peptide disorder, acetylcholinesterase inhibitor, serine/threonine kinase (Akt) activator, phosphatidylinositol(3,4,5)-3-phosphokinase (PI3K)-serine/threonine kinase (Akt) cascade activator, accelerator for increasing cyclic AMP concentration, or SAPK/JNK phosphorylation inhibitor. |
| Current U.S. Class: |
51425/408 |
| Current International Class: |
61; 07; 07; 07; 07; 07; 07; 07; 61; 61; 61; 61; 61; 61; 61; 61; 61; 61; 61; 61; 61; 61; 61; 07 |
| رقم الانضمام: |
edspap.20120035187 |
| قاعدة البيانات: |
USPTO Patent Applications |
